AllPennyStocks.com EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term

The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
This Cannabis Microcap Just Bought Its Way Into Two of Europe's Biggest Markets
BC Copper-Gold Explorer Surges 40% on Maiden Drill Visuals
Most Popular
{{ index + 1 }}


Back to Top